September 21, 2017
Chronic tissue inflammation resulting from obesity is an underlying cause of insulin resistance and type 2 diabetes. But the mechanism by which this occurs has remained cloaked, until now. In a paper, University of California San Diego School of Medicine researchers identified exosomes — extremely small vesicles or sacs secreted…
January 20, 2017
…use of stem cell-derived natural killer (NK) cells to target ovarian cancer and other malignancies.
August 25, 2021
The California Institute for Regenerative Medicine has approved a trio of awards, totaling approximately $4 million, to UC San Diego School of Medicine researchers to advance studies of new stem cell-based treatments for multiple types of cancer and amyotrophic lateral sclerosis.
April 21, 2016
Thanks to combination antiretroviral therapies, many people with HIV can expect to live decades after being infected. Yet doctors have observed these patients often show signs of premature aging. Researchers at University of California San Diego School of Medicine and the University of Nebraska Medical Center have applied a highly…
June 22, 2020
UC San Diego researchers uncovered in mice how IRE1α, a molecule involved in cells’ response to stress, determines whether macrophages promote inflammation in the tumor microenvironment. Inflammation is known to promote tumor growth, making IRE1α an attractive target for drug development.
June 26, 2020
UC San Diego and Deerfield Management created Poseidon Innovation to support researchers working to advance disease-curing therapeutics by funding early stage projects and expediting the drug-development cycle. Poseidon announces it is funding three researchers.
June 11, 2020
Using induced pluripotent stem cells (iPSCs) and deleting a key gene, researchers at University of California San Diego School of Medicine have created natural killer cells — a type of immune cell — with measurably stronger activity against a form of leukemia, both in vivo and in vitro.
September 21, 2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers may have found a way to double down on immunotherapy’s effectiveness.
April 1, 2019
Moores Cancer Center at UC San Diego Health treats the first patient treated for cancer with a human-induced pluripotent stem cell (iPSC)-derived cell therapy called FT500. Dan Kaufman collaborated with Fate Therapeutics to bring the iPSC-derived natural killer cell cancer immunotherapy to patients.
October 9, 2013
A research team, headed by Theodore Friedmann, MD, professor of pediatrics at the University of California, San Diego School of Medicine, says a gene mutation that causes a rare but devastating neurological disorder known as Lesch-Nyhan syndrome appears to offer clues to the developmental and neuronal defects found in other,…
